Dec 8, 2020 | Education Program, Tuesday
Advertisement Angela Weyand, MD Twitter Treatment of lymphoma has come a long way since the 1600s when it was first described by Dr. Marcello Malpighi as “a disease of lymph nodes and spleen that was uniformly fatal.” Recent advances, ranging from chimeric antigen...
Dec 8, 2020 | Education Program, Tuesday
Advertisement Katherine Regling, DO Twitter Alexander Glaros, MD Twitter “You have brains in your head. You have feet in your shoes. You can steer yourself any direction you choose.” I love this book. I love Dr. Seuss. Oh, the Places You’ll Go! by Dr. Seuss reminds me...
Dec 7, 2020 | General Sessions, Monday
Advertisement Ahmar U. Zaidi, MD Twitter “There are more lymphoma mutations than there are labs that study lymphoma mutations,” Dr. Ari Melnick of Weill Cornell Medicine told me over a Zoom chat. He was trying to express that precision medicine in lymphoma is not an...
Dec 10, 2019 | 2019, 2019 Special-Interest Sessions, 2019 Tuesday
By Basem M. William, MD On Monday, the Director of the Division of Hematology Products in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA), Ann Farrell, MD, chaired the two special ASH-FDA Joint Symposia focusing on new...
Dec 9, 2019 | 2019, 2019 Education Program, 2019 Monday
By Basem M. William, MD One of the major leaps in hematopoietic stem cell transplantation (HSCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to approximately 75 percent of patients who do...
